Journal of the American Heart Association · 2026
Association of F11 Gene Variants With Cardiovascular Events and Cardiac Function.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ye Qianxi, Hu Shengtao, Yang Rui, Lai Yilin, Chen Zhang, Li Jiajun, Zhao Haige, Wu Jiayuan, Ma Liang, Dai Zhijun
Аннотация
BACKGROUND: FXI (Factor XI) inhibitors have emerged as a promising antithrombotic strategy. However, a recent study linked decreased FXI levels with increased risk of heart failure (HF) and atrial fibrillation (AF), particularly in older adults. This study aims to investigate the associations of genetic FXI inhibition with cardiovascular events and cardiac function.
METHODS: This prospective study included 408 642 UK Biobank participants of European ancestry. Two F11-based genetic scores were constructed, weighted separately by their associations with activated partial thromboplastin time or circulating FXI levels. Adjusted Cox or linear regression models were built to predict incident HF, AF, and cardiac magnetic resonance measures. Interactions with age and age-related cardiometabolic traits were tested.
RESULTS: Over 14.6 years median follow-up, 14 451 participants developed incident HF, and 29 243 developed incident AF. The FXI activated partial thromboplastin time score was not associated with HF, AF, or cardiac magnetic resonance measures overall. In exploratory interaction analyses, baseline hemoglobin A1c (HbA1c) modified its association with HF (P<0.001) and AF (P=0.027), with higher HF risk observed among participants with HbA1c≥7% (hazard ratio per 10% genetically predicted increase in activated partial thromboplastin time, 1.65 [95% CI, 1.13-2.40]) but not in those with HbA1c<7%. No association was observed with AF across HbA1c strata. Similar patterns were observed for the FXI level score.
CONCLUSIONS: Genetically proxied FXI inhibition was not associated with HF, AF, or cardiac magnetic resonance-derived cardiac measures overall, but its associations with HF and AF may be modified by HbA1c. Future studies are needed to verify these exploratory findings.
METHODS: This prospective study included 408 642 UK Biobank participants of European ancestry. Two F11-based genetic scores were constructed, weighted separately by their associations with activated partial thromboplastin time or circulating FXI levels. Adjusted Cox or linear regression models were built to predict incident HF, AF, and cardiac magnetic resonance measures. Interactions with age and age-related cardiometabolic traits were tested.
RESULTS: Over 14.6 years median follow-up, 14 451 participants developed incident HF, and 29 243 developed incident AF. The FXI activated partial thromboplastin time score was not associated with HF, AF, or cardiac magnetic resonance measures overall. In exploratory interaction analyses, baseline hemoglobin A1c (HbA1c) modified its association with HF (P<0.001) and AF (P=0.027), with higher HF risk observed among participants with HbA1c≥7% (hazard ratio per 10% genetically predicted increase in activated partial thromboplastin time, 1.65 [95% CI, 1.13-2.40]) but not in those with HbA1c<7%. No association was observed with AF across HbA1c strata. Similar patterns were observed for the FXI level score.
CONCLUSIONS: Genetically proxied FXI inhibition was not associated with HF, AF, or cardiac magnetic resonance-derived cardiac measures overall, but its associations with HF and AF may be modified by HbA1c. Future studies are needed to verify these exploratory findings.